Clinical Trial

Improving Healthcare Outcomes With Early Detection of Liver Related Complications in Liver Cirrhosis Patients by Implementing a Telemedicine Care Pathway (myLIVERcoach)

Study acronym: myLiverCOACH
Completed
View on ClinicalTrials.gov →
Summary
The goal of this multicenter feasibility study is to investigate the feasibility of our telemedicine platform (myLIVERcoach) in liver cirrhosis patients, according to liver cirrhosis patients, caregivers and healthcare professionals. The main question\[s\] it aims to answer are: 1. What is the feasibility of a telemonitoring pathway according to patients, caregivers and healthcare professionals in liver cirrhosis care? Secondary objectives: 2. What is the level of acceptability, usability, learnability and desirability of a telemonitoring pathway in liver cirrhosis care from the patients, caregivers and healthcare professionals' perspective? 3. What is the level of compliance of patients, caregivers and healthcare professionals using a telemonitoring pathway in liver cirrhosis care? 4. What is the occurrence of liver related complications in liver cirrhosis patients using a telemonitoring pathway? 5. What is the occurrence of clinical admissions and emergency concultations in liver cirrhosis patients using a telemonitoring pathway? 6. What is the mortality rate in liver cirrhosis patients using a telemonitoring pathway? 8\. What is the effect of a telemonitoring pathway on patients perceived health, quality of life and work participation of liver cirrhosis patients? Participants will be asked to use myLIVERcoach on top of standard care. According to disease stadium participants will receive different online questionnaires and measurements, focusing on early detection of complications and psychosocial and lifestyle factors. Participants are able to contact their healthcare professional and go through information about their disease as well. After six months, participants will be asked to fill out a questionnaire regarding their experiences with myLIVERcoach in order to optimize the system. In addition the investigators will perform interviews with ten patients or caregivers and with healthcare professionals at the end of follow-up.
Trial Details
NCT Number NCT07376967
Lead Sponsor Maastricht University
Collaborators: Dutch Digestive Diseases Foundation, Gelre Hospitals, Maastricht University Medical Center
Conditions Liver Cirrhosis
Enrollment 50 participants
Start Date 2023-05-01
Primary Completion 2025-05-01 (estimated)
Study Completion 2025-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-29